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Background. Glioma stem cells (GSCs) from human glioblastomas (GBMs) are resistant to radiation and chemotherapy and may
drive recurrence. Treatment efficacymay depend on GSCs, expression of DNA repair enzymes such as methylguaninemethyltrans-
ferase (MGMT), or transcriptome subtype.
Methods. To model genetic alterations in human GBM core signaling pathways, we induced Rb knockout, Kras activation, and Pten
deletion mutations in cortical murine astrocytes. Neurosphere culture, differentiation, and orthotopic transplantation assays were
used to assess whether these mutations induced de-differentiation into GSCs. Genome-wide chromatin landscape alterations and
expression profiles were examined by formaldehyde-assisted isolation of regulatory elements (FAIRE) seq and RNA-seq. Radiation
and temozolomide efficacy were examined in vitro and in an allograft model in vivo. Effects of radiation on transcriptome subtype
were examined by microarray expression profiling.
Results. Cultured triple mutant astrocytes gained unlimited self-renewal andmultilineage differentiation capacity. These cells har-
bored significantly altered chromatin landscapes that were associated with downregulation of astrocyte- and upregulation of
stem cell-associated genes, particularly the Hoxa locus of embryonic transcription factors. Triple-mutant astrocytes formed seri-
ally transplantable glioblastoma allografts that were sensitive to radiation but expressed MGMT and were resistant to temozolo-
mide. Radiation induced a shift in transcriptome subtype of GBM allografts from proneural to mesenchymal.
Conclusion. A defined set of core signaling pathway mutations induces de-differentiation of cortical murine astrocytes into GSCs
with altered chromatin landscapes and transcriptomes. This non-germline genetically engineered mouse model mimics human
proneural GBM on histopathological, molecular, and treatment response levels. It may be useful for dissecting the mechanisms of
treatment resistance and developing more effective therapies.
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Brain tumors are among the most devastating of all human
cancers. Survival for glioblastoma (GBM), the most common
and biologically aggressive brain tumor, averages 12–15
months.1 Standard therapy for newly diagnosed GBM patients
consists of surgery followed by radiation therapy (XRT) with
concurrent and adjuvant temozolomide (TMZ). This regimen
produces a modest, 3-month improvement in survival
compared with XRT alone but invariably fails to prevent tumor
recurrence.2
Factors that may drive GBM recurrence include the presence
of cancer stem cells (CSCs), inherent resistance to DNA-
damaging therapies, and transcriptome subtype. The CSC hy-
pothesis posits that tumor cells with stem cell-like properties
(referred to generically as CSCs or specifically as brain tumor
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or glioma stem cells [GSCs]) are responsible for tumor mainte-
nance.3–5 GSCs share properties with neural stem cells (NSCs),
including their capacity to undergo unlimited self-renewal and
to differentiate into multiple neural cell lineages, and can gener-
ate the full cellular complexity of a tumor. GSCsmay be inherently
resistant to XRT and many chemotherapeutic agents and thus
may be responsible for tumor recurrence.6,7 The DNA repair pro-
tein MGMT, an enzyme dedicated to repair of alkyl-nucleotide ad-
ducts, is an importantmodulator of chemoresistance to alkylating
agents used in GBM treatment including TMZand the nitrosoureas
carmustine (BCNU) and lomustine (CCNU).8,9 Methylation-based
silencing of theMGMTpromoter has been proposed as a predictive
biomarker for identifying TMZ responders.8–10 Genomic analyses
of GBM have identified frequently mutated genes in 3 core signal-
ing pathways: the G1/S cell cycle checkpoint (Rb), receptor tyro-
sine kinase (RTK)/mitogen activated protein kinase (MAPK)/
phosphoinositide 3 kinase (PI3K), and TP53 pathways.11 Transcrip-
tome profiling has been used to classify GBM into 4 molecular
subtypes (proneural, neural, classical, andmesenchymal) with in-
herent differences in response to DNA-damaging therapies such
as XRT and TMZ.10–14
Genetically engineered mouse (GEM) models faithfully reca-
pitulate the molecular genetics and biology of human gliomas.
These models have emerged as an essential experimental tool
for investigating glioma genetics and evaluating novel thera-
peutics.15,16 We previously developed a non-germline GEM
(nGEM) model of GBM using cortical astrocytes harvested
from mice with conditional oncogenic alleles in core signaling
pathway genes. Mutations that ablate the G1/S checkpoint
and activate MAPK and PI3K signaling—specifically inhibition
of the Rb family of pocket proteins via an N-terminal, 121
amino acid truncation mutant of SV40 large T antigen (T121, T)
expressed from the human glial fibrillary acidic protein (GFAP)
promoter, a constitutively active Kras mutant (KrasG12D, R), and
deletion of the negative PI3K regulator Pten (P), respectively—
transform cultured TRP astrocytes, modulate their metabolism,
and induce a primitive, proneural GBM-like gene expression
state.17–19 Moreover, orthotopic injection of TRP astrocytes into
the brains of syngeneic, immunocompetent mice produces rap-
idly fatal GBM.17
Here we demonstrate that TRP mutations induce astrocyte
de-differentiation and that these cells have altered chromatin
landscapes and gene expression profiles. TRP astrocytes gain
the functional properties of GSCs in vitro and develop into seri-
ally transplantable GBMwhen as few as 100 cells are orthotopi-
cally allografted in vivo. We then examine the role of MGMT in
TMZ sensitivity and transcriptome response to XRT. TRP astro-
cytes and allografts express MGMT and are resistant to TMZ.
XRT induces a transient inhibition of tumor growth and a signif-
icant increase in survival. Transcriptome analyses show that
TRP allografts are enriched for human proneural GBM signa-
tures and that XRT induces a mesenchymal shift in transcrip-
tome phenotype, similar to its effects in human GBM.12,13
Materials and Methods
Genetically Engineered Mice
Crossing heterozygous conditional TgGZT121 (T), heterozygous
KrasG12D conditional knock-in (R), and/or homozygous conditional
Pten knock-out (P) mice generated compound T, TR, and TRP
mice.17,20,21 PCR genotyping was performed as previously de-
scribed.17 The University of North Carolina Institutional Animal
Care and Use Committee approved all animal studies.
Orthotopic Allografts and Xenografts
Mutant astrocytes were allografted into syngeneic C57Bl/6
hosts as previously described.17 Xenograft experiments used
athymic nude mice (Charles River), which were orthotopically
injected with U87FL cells.22
Microarray and Sequencing Data
Original microarray (GSE59116) and sequencing (GSE75592)
data have been deposited into Gene Expression Omnibus.
Statistics
Data were analyzed with GraphPad Prism 5 or Stata 12 (Stata-
Corp). All comparisons were considered significant at a¼ 0.05.
Results
Core Glioblastoma Pathway Mutations Induce Astrocyte
De-differentiation Into Glioma Stem Cells
We have shown that RP mutations activate MAPK and PI3K sig-
naling in T121-expressing astrocytes with a defective G1/S
checkpoint and cooperate to potentiate proliferation, migra-
tion, and invasion in vitro. Moreover, triple-mutant TRP astro-
cytes are tumorigenic, producing tumors with histology
similar to human GBM in vivo.17,18However, it remained unclear
whether they also induced GSC phenotypes.
GSCs express NSC markers, display unlimited self-renewal,
are capable of multilineage differentiation, and are tumorigenic
when serially transplanted into mouse brains. We first exam-
ined whether TRP astrocytes gained expression of NSC/GSC
markers (Supplementary material, Fig. S1, Supplementary ma-
terial, Table S1). NSCs harvested from the subventricular zone of
wild-type mice expressed CD133, Sox2, and Nestin, and a sub-
set expressed GFAP (Supplementary material, Fig. S1A). Wild-
type astrocytes expressed GFAP but lacked NSC/GSC markers
(Supplementary material, Fig. S1B). TRP astrocytes maintained
GFAP, and Cre recombination induced T121, CD133, Sox2, and
Nestin expression (Supplementary material, Fig. S1C). These
results indicate that TRP mutations induce NSC/GSC marker
expression in cultured astrocytes.
Self-renewal capacity was examined by growing TRP astro-
cytes as nonadherent neurospheres in growth factor-defined
media. Neurospheres could be serially propagated for at least
6 passages, and frequency was comparable to wild-type NSCs
(Fig. 1A). Wild-type and un-recombined TRP astrocytes failed to
form neurospheres (data not shown). These results suggest
that TRP astrocytes undergo unlimited self-renewal similar to
wild-type NSCs.
We next examined whether TRP neurospheres weremultipo-
tent. Reintroduction of serum induced differentiation into
GFAP+ astrocytes (Fig. 1B), NG2+ oligodendrocyte progenitor
cells (OPCs), and Tuj1+ neurons (Fig. 1C). Similar results were
obtained with wild-type NSC neurospheres (data not shown).
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These results demonstrated that TRP mutations induce astro-
cyte de-differentiation and that these cells acquire NSC proper-
ties in vitro.
We also examined Tand TR astrocytes to determinewhether
RP mutations were required to induce de-differentiation. Since
T, TR, and TRP astrocytes could be serially propagated as neuro-
spheres in defined media, we estimated the frequency of stem
cells in each using an extreme limiting-dilution assay (Fig. 2A).
Wild-type astrocytes failed to form neurospheres in this assay
as well (data not shown). TRP astrocytes contained significantly
more neurosphere-forming stem cells than T and TR astrocytes
but less than NSCs (Supplementary material, Fig. S2A). Howev-
er, serum induced multilineage differentiation in all 3 geno-
types (Fig. 2B and Supplementary material, Fig. S2B–D). Thus,
while T and TR astrocytes acquired NSC properties, their stem
cell frequency was significantly less than TRP astrocytes.
These results suggested that ablation of the G1/S checkpoint
by T121 alone is sufficient to form multipotent neurospheres,
but all 3 mutations are required to significantly increase stem
cell frequency.
In addition to NSC properties, GSCs are also capable of pro-
ducing tumors upon serial transplantation. Indeed, TRP astro-
cytes produced astrocytomas in 100% of injected mice, and
survival was highly reproducible (Supplementary material,
Fig. S3A). GBM developed in all secondary and tertiary hosts,
and survival was identical (Fig. 1D). Furthermore, serial dilutions
produced a dose-dependent increase in survival, but all mice
succumbed to GBM from as few as 100 transplanted cells
(Fig. 1E and Supplementary material, Fig. S3B). These findings
are consistent with the 1%–2% neurosphere-forming efficien-
cy in vitro (Fig. 1A). Taken together, these results demonstrate
that TRP astrocytes behave as GSCs in vivo.
Because the vast majority of TRP-allografted mice devel-
oped GBM when aged to neurological morbidity, we examined
whether these tumors progressed histologically. Mice were sys-
tematically euthanized at 5-day intervals, and their brains were
examined (Supplementary material, Figs. S3C and S4). At 5
days, 60% of mice had developed small, mitotically active an-
aplastic astrocytomas (WHO grade III) that diffusely invaded
brain parenchyma (Supplementary material, Fig. S4A–C). By
20 days, all mice had developed progressively larger, mitotically
active GBM (WHO grade IV) with microvascular proliferation
and necrosis (Supplementary material, Fig. S4J–L). Only 30%
of mice injected with T astrocytes developed small low-grade
astrocytomas (,1 mm2) that required 12 months to grow
(Fig. 2C–E).17 TR astrocytes produced tumors less frequently
(16%), but these were larger and higher grade and required sig-
nificantly less time to develop. In contrast, mice injected with
TRP astrocytes developed large, high-grade tumors that re-
quired markedly less time to develop. These results suggest
that while T and TR astrocytes acquire NSC properties in vitro,
simultaneous ablation of the G1/S checkpoint and activation
of both MAPK and PI3K signaling are required to convert astro-
cytes into highly potent, tumorigenic GSCs in vivo.
Fig. 1. TRP astrocytes acquire glioma stem cell features in vitro and in vivo. Neurosphere self-renewal of TRP astrocytes was indistinguishable from
wild-type neural stem cells (P≥ .1). Scale bar¼ 50 mm (A). Serum-induced differentiation of nestin+ TRP neurospheres into glial fibrillary acidic
protein-positive astrocytes (B), NG2+ oligodendroglia, and Tuj1+ neurons (C). Scale bar¼ 10 mm. Primary TRP allografts were serially
transplantable into secondary and tertiary host brains. Median survival (26–27 d) was indistinguishable (P¼ .8), and all mice developed
glioblastoma (D). A cell dose-dependent (102–106) increase in median survival (23–45 d) was evident (P, .0001, E).
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Core Glioblasoma Pathway Mutations Induce Global
Changes in the Astrocyte Chromatin Landscape
Differentiation and cellular identity are epigenetically regulat-
ed. Genome-wide profiling methods, such as formaldehyde-
assisted isolation of regulatory elements (FAIRE)-seq, have
been developed to globally assess chromatin landscapes and
the role of open chromatin regions (regulatory elements) in cel-
lular identity.23,24 We therefore used FAIRE-seq to define open
chromatin regions in cultured wild-type astrocytes and assess
how mutations altered their chromatin landscape. Hierarchical
clustering (Fig. 3A) and principal components analysis (Fig. 3B)
on highly variable regions (Supplementary material, Table S2)
showed that the chromatin landscapes of all 4 genotypes
were distinct. Regions clustered into 4 classes, each enriched
in particular astrocyte genotypes. TRP astrocyte-enriched re-
gions contained genes shown to promote GBM tumorigenesis
including Vav3 (Fig. 3C) and Hdac9 (Fig. 3D).25,26 Regions en-
riched in wild-type astrocytes contained genes shown to
decrease GSC tumorigenesis including Snai1 (Fig. 3E).27
Next, we used bioinformatic tools to identify enriched
ontologies of nearby genes and motifs corresponding to
known transcription factors within regions of open chromatin.
TRP astrocyte-enriched regions demonstrated linkages with
developmental and stem cell processes (Supplementary mate-
rial, Table S3). Although sites within all 4 classes harbored mo-
tifs for important stem cell transcription factor families, only
the TRP-enriched cluster contained multiple families including
Nanog and Sox (Fig. 3F).
RNA-seq analysis of TRP and wild-type astrocytes revealed
significant alterations in the mutated astrocyte transcriptome
(2257 of 20 733 genes, 10.9%, Fig. 4A, Supplementary materi-
al, Table S4). TRP mutations induced downregulation of
astrocyte signature genes (Fig. 4B, Supplementary material,
Table S5) and upregulation of stem cell-related genes.28–31 De-
creased expression of the astrocyte-specific genes Aqp4
(Fig. 4C), Aldh1l1, and Fgfr3 (data not shown) correlated with
decreased promoter chromatin accessibility (Supplementary
material, Table S6). In contrast, promoters within the Hoxa
locus on chromosome 6 showed increased accessibility, and
Fig. 2. G1/S ablation and activating MAPK and PI3K mutations are required to induce efficient astrocyte de-differentiation and tumorigenesis. TRP
astrocytes contained significantly more neurosphere-forming stem cells than T and TR astrocytes but less than neural stem cells (1 in 21)
(Supplementary material, Fig. S2A) (A). Serum-induced differentiation of T, TR, and TRP neurospheres into glial fibrillary acidic protein-positive
astrocytes, NG2+ oligodendroglia, and Tuj1+ neurons (B). TRP astrocytes developed into astrocytomas in all mice, but T and TR astrocytes failed
to develop tumors in .70% (P, .0001, C). Mice injected with 105 TRP astrocytes required significantly less time (26.0+0.6 d) to develop tumors
than T (345+13.6 d) and TR (216+10.6 d) astrocytes (P, .0001, D). T astrocyte tumors were significantly smaller (mean 0.4+0.2 mm2) than TR
(mean 7.4+2.8 mm2) or TRP (mean 8.9+0.6 mm2) astrocyte tumors (P¼ .016, E). N, number of mice examined; NL, normal; A2, diffuse
astrocytoma (WHO grade II); A3, anaplastic astrocytoma (WHO grade III); GBM, glioblastoma (WHO grade IV). Scale bars¼ 10 mm.
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Hoxa1-7 and Hoxa9 expression was increased .4-fold in TRP
astrocytes (Fig. 4D, Supplementary material, Tables S4 and S6).
The Hox family of stem-cell transcription factors are important
for embryonic development, and their dysregulated expression
has been found in various cancers including GBM.32,33 To deter-
mine whether these gene expression changes were significant
among all significantly altered pathways, we performed and
aggregated an analysis of gene ontologies (Supplementary
material, Table S7). We found that TRP astrocytes exhibited
upregulation of genes involved with cell growth and embryonic
development (Fig. 4E) and a concomitant loss of neural and cell
adhesion–related processes (Fig. 4F).
TRP Astrocytes Are Sensitive to Radiation Therapy but Are
Resistant to Temozolomide due to MGMT
Fractionated XRT and TMZ are standard therapy for GBM.2 GSCs
are frequently resistant to these therapies.6,7 We therefore
Fig. 3. TRP mutations induce genome-wide alterations in the chromatin landscape of astrocytes. Highly variable intervals (300 bp) of open
chromatin were analyzed by hierarchical clustering. Regions of increased chromatin accessibility were enriched in TRP, T and TRP, TR, or
wild-type astrocytes (AC) (A). Principal component analysis confirmed that chromatin landscapes of these cells were distinct (B).
Representative genes from TRP-enriched (CD) and AC-enriched (E) regions are shown. Target motifs specific to particular transcription factor
(TF) families were enriched in each class, but only the TRP class harbored motifs from multiple families of stem-cell TF (F).
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Fig. 4. TRP mutations induce downregulation of astrocyte markers and upregulation of stemness genes. Differential expression analysis showed
that TRP mutations induced significant transcriptome alterations (10.9%, q, 0.001) relative to wild-type astrocytes (A), including downregulation
of published astrocyte gene signatures (B, FDR, 0.01). Decreased expression of the astrocyte-specific gene Aqp4 (C) and increased expression of
the Hoxa locus of stem cell transcription factors (D) anti-correlated with chromatin accessibility alterations within 70KB of their transcriptional start
sites. An aggregated gene ontology analysis showed upregulation of cell growth and embryonic development (E) and downregulation of neural
and cell adhesion-related processes (F). FDR values are colored; diameter indicates term frequency.
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examined whether TRP astrocytes were sensitive to XRT and
TMZ. To provide a frame of reference, human U87 cells were
also examined because they have been widely studied, and
their sensitivity to cytotoxic therapies has been defined.22,34,35
XRT sensitivity of TRP astrocytes was similar to U87 (Fig. 5A) and
other human GBM cell lines.22,36,37 TMZ inhibited U87 growth at
31-fold lower concentrations than TRP astrocytes (Fig. 5B) and
induced G2/M arrest only in U87 cells (Supplementary material,
Fig. S5). Because TMZ IC50 was .10-fold higher than maximal
plasma levels of orally administered TMZ (50 mM), we conclud-
ed that TRP astrocytes are highly resistant to TMZ in vitro.38 To
examine whether TRP mutations induced acquired resistance,
TMZ sensitivity of wild-type, T, and TR astrocytes as well as wild-
type NSCs was also examined. All were highly resistant, sug-
gesting that resistance was not acquired during the process
of transformation (Supplementary material, Fig. S6).
Expression of the DNA repair enzyme MGMT is an established
TMZ resistance mechanism.8 MGMT expression was therefore
examined in TRP astrocytes, wild-type NSCs, and astrocytes
by immunoblot. All 3 expressed similar levels of MGMT (Supple-
mentary material, Fig. S7A and B), but MGMT was 3.5-fold higher
in TRP astrocytes than U87 cells (Fig. 5C). These results suggest
that TRP astrocytes, as well as wild-type NSCs, are resistant to
TMZ due to MGMT. To confirm this hypothesis, O6-benzylguanine
(O6-BG) was used to inhibit MGMTpharmacologically. O6-BG pro-
duced a dose-dependent increase in TMZ sensitivity, and IC50
decreased 10-fold in the presence of 75 mM O6-BG (Fig. 5D
and E). O6-BG did not significantly alter U87 response (Supple-
mentary material, Fig. S7C and D), a finding consistent with
other established human GBM cell lines.39 TRP astrocytes and
U87 cells responded similarly to 2 mechanistically related DNA
alkylating agents, the nitrosoureas BCNU and CCNU (Supplemen-
tary material, Fig. S8A and B), and neither was sensitive at plas-
ma concentrations (10 mM) achieved in patients.35,36 MGMT
inhibitionwith O6-BG did not alter sensitivity to these drugs (Sup-
plementary material, Fig. S8C and D). To determine whether TRP
astrocyte resistance was specific for alkylating agents or applied
more globally to other cytotoxic agents, their sensitivity to
SN-38, an active metabolite of the mechanistically distinct topo-
isomerase I inhibitor irinotecan, was examined. Both TRP astro-
cytes and U87 cells were sensitive to SN-38 (Supplementary
material, Fig. S8E) at concentrations well below those achieved
clinically (250 nM).40 These results suggest that TRP astrocytes
are inherently resistant to DNA alkylating agents, but not other
cytotoxic drugs, and that MGMT contributes to their TMZ
resistance.
TRP Allografts Are Sensitive to Radiation Therapy but
Resistant to Temozolomide
Efficacy of TMZ, XRT, or their combination was examined inmice
bearing established orthotopic TRP allografts. TMZ dose and
Fig. 5. TRP astrocytes are sensitive to XRT but resistant to TMZ due to MGMT. TRP astrocytes and U87 cells were sensitive to XRT (P¼ .26) (A). U87
cells (IC50 21 mM, 95% CI: 13–33 mM) but not TRP astrocytes (IC50 647 mM, 95% CI: 409–1024 mM) were sensitive to TMZ (P, .0001) (B). MGMT
levels were 3.5-fold higher in TRP astrocytes (P, .0001) (C). The MGMT inhibitor O6-BG produced a dose-dependent increase in TMZ sensitivity in
TRP astrocytes (P, .0001) (D). TMZ IC50 fold change from D is shown in E.
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schedule were designed to achieve similar drug exposure in pa-
tients receiving 5 daily doses at 200 mg/m2.2 Like cultured TRP
astrocytes, TRP allografts expressed MGMT (Supplementary
material, Fig. S9A). XRT, but not TMZ, significantly prolonged
survival (Fig. 6A). The combination decreased malignant pro-
gression (Supplementary material, Fig. S9B), but the addition
of TMZ did not produce a survival benefit compared with XRT
alone (Fig. 6A). Regardless of treatment, all mice eventually de-
veloped fatal astrocytomas, and the vast majority were GBMs
(Supplementary material, Fig. S9B). MRI-detectable tumors de-
veloped by day 7 in control (untreated) mice, but similarly sized
tumors appeared 10 days later in XRT-treated mice (Fig. 6B).
XRT thus induced a transient arrest in tumor growth, but all
mice succumbed from recurrent tumor.
To examine whether XRT efficacy was dependent on
schedule, mice were treated with a similar total dose
(16 Gy) delivered in smaller, 2 Gy daily fractions. This regimen
was not as effective as 15 Gy delivered in three 5 Gy fractions,
but it also significantly prolonged survival of TRP allograft
mice (Supplementary material, Fig. S10A) and decreased pro-
gression to GBM (Supplementary material, Fig. S10B). We next
examined whether XRT was effective in TRP allografts that
had progressed to GBM (Supplementary material, Fig. S3C)
by delaying treatment to day 17. XRT significantly prolonged
survival of these mice as well (Supplementary material,
Fig. S10C and D).
XRT also slowed growth of luciferase-expressing TRP-Luc
allografts (Fig. 6C) and significantly increased survival (Supple-
mentary material, Fig. S11A). In contrast, XRT delayed growth
but did not prolong survival of immunodeficient mice bearing
orthotopic, luciferase-expressing U87FL xenografts (Supple-
mentary material, Fig. S11B and C). Taken together, these
results demonstrated that allografts derived from de-
differentiated TRP astrocyte GSCs are sensitive to XRT but resis-
tant to TMZ, due in part to their expression of MGMT.
Radiation Therapy Induces a Proneural-to-mesenchymal
Shift in Transcriptome Subtype
We have shown that activating MAPK and PI3K mutations in-
duces a primitive, proneural GBM-like gene expression state in
cultured TRP astrocytes.13,17 Single-sample gene set enrich-
ment analysis showed that the transcriptomes of untreated
TRP allografts were also enriched for proneural signatures de-
fined by The Cancer Genome Atlas (TCGA, Fig. 6D and Supple-
mentary material, Fig. S11D) and Phillips et al (data not
shown) in human GBM and high-grade astrocytomas, respec-
tively.12,13 Transcriptome profiling of matched pairs of newly
Fig. 6. Radiation therapy (XRT), but not temozolomide (TMZ), is effective in TRP allografts and induces a proneural-to-mesenchymal transcriptome
shift. XRT (33 days, P, .0001), but not TMZ (22 days, P¼ .8), significantly prolongedmedian survival of TRP allograftmice (21 d). Adding TMZdid not
extend survival (32 d) relative to XRT alone (P¼ .5) (A). XRT produced a significant decrease in TRP allograft growth rate by longitudinal MRI
(doubling time 3.3 vs 1.8 d, P¼ .002) (B). XRT induced a similar decrease in TRP-Luc allograft growth by longitudinal BLI (doubling time 35 vs
7.7 d, P, .0001) (C). Transcriptomes of control, untreated TRP allografts were most similar to human proneural (PN) glioblastoma (GBM) (P¼
.0005). XRT induced a shift to mesenchymal (MES) GBM (P¼ .01) rather than classical (CL) or neural (NL) subtypes (P≥ .2).
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diagnosed and recurrent high-grade astrocytomas from indi-
vidual patients has shown that proneural tumors undergo a
shift to themesenchymal phenotype after therapy.12 We there-
fore examined whether XRT induced a similar shift in TRP allo-
graft transcriptomes. Indeed, the majority of recurrent TRP
allografts were enriched for TCGA (Fig. 6D and Supplementary
material, Fig. S11D) and Phillips (data not shown) mesenchy-
mal GBM signatures. Moreover, a mesenchymal shift was also
evident in the tumor microenvironment including histological
evidence of mesenchymal (spindle cell) differentiation and in-
creased expression of the mesenchymal GBM marker, vimentin
(Supplementary material, Fig. S12). We therefore concluded
that the TRP astrocyte-derived nGEM model mimics human
proneural GBM on the histopathological, molecular, and treat-
ment response levels.
Discussion
We have shown that G1/S ablation by T121 alone is sufficient to
induce de-differentiation of astrocytes into NSC-like cells in
vitro. However, mutations that activate both MAPK and PI3K
signaling were required to fully convert G1/S-defective astro-
cytes into GSCs capable of forming serially transplantable
GBM in vivo. Similar results have been described with Ink/arf-/-
murine astrocytes that lack both gene products encoded by
Cdkn2a: the G1/S pathway protein p16Ink4a and the Trp53 path-
way protein p19Arf.41 In contrast to astrocytes deficient for
p16Ink4a, p19Arf, or Trp53 alone, deletion of both Cdkn2a
genes was required to induce de-differentiation in vitro. Howev-
er, Ink/arf-/- astrocytes were nontumorigenic. Rather, a consti-
tutively active RTKmutation, the EGFRvIII truncation frequently
found in human GBM, was required to induce high-grade glio-
mas in vivo. Similar results have also been described for
Trp53-deficient astrocytes with activating MAPK mutations in-
cluding Nf1 deletion or HrasV12.42 In contrast to astrocytes de-
ficient for Trp53 or expressing activated HrasV12 alone, both
Trp53 deletion and activating MAPK mutations were required
to induce astrocyte de-differentiation in vitro and induce high-
grade gliomas in vivo. Taken together, these results suggested
that de-differentiation may be induced by multiple G1/S, RTK
(MAPK and PI3K), and TP53 pathway mutations in gliomas of
astrocyte origin.
We have extended these previous reports by showing that
core GBM pathway mutations induce significant alterations in
the astrocyte chromatin landscape and transcriptome. TRP as-
trocytes contained regions of accessible chromatin associated
with genes shown to promote tumorigenesis, such as Vav3 and
Hdac9, as well as regions of inaccessible chromatin associated
with genes that inhibit GBM tumorigenesis such as Snai1.
Accessible chromatin regions also harbored binding motifs en-
riched for multiple families of stem cell-associated transcrip-
tion factors including Sox and Nanog.43,44 RNA-seq analysis
showed that TRP astrocytes mutations harbored inaccessible
chromatin and downregulated expression of astrocyte signa-
ture genes including Aqp4, Aldh1l1, and Fgfr3. In contrast,
stem-cell– related genes harbored accessible chromatin and
increased expression including Hoxa locus genes (Hoxa1,
Hoxa5), Sox1, Sox5, Sox9, and Nfia. These stem cell transcription
factors are important for embryonic development, and their
dysregulated expression has been found in various cancers in-
cluding GBM.32,33,45,46 These data suggest that transcription
factors promoting stemness in transformed astrocytes may
themselves be differentially regulated or have differential activ-
ity because of large-scale changes in their accessible chromatin
landscape. Changes at the chromatin level may thus force tran-
scription factors to alter their localization, likely driving the pre-
viously characterized gene expression differences in TRP versus
T and TR astrocytes.17
The G1/S checkpoint genes CDKN2A and RB1 were mutated
in 61% and 9% of 281 human GBM analyzed by TCGA, respec-
tively. Mutations in these genes were mutually exclusive (log
odds ratio 21.9, P, .0001). Virtually all CDKN2A mutations
were homozygous deletions affecting both Ink4a and Arf
gene products. TP53mutations were found in 22% of these tu-
mors and were mutually exclusive with CDKN2A (log odds ratio
21.4, P, .0001), but co-occurred with RB1mutations (log odds
ratio21.8, P, .0001).14,47 These findings suggest that simulta-
neous ablation of the G1/S checkpoint and TP53 pathways, ei-
ther by CDKN2A deletions alone or mutations in both RB1 and
TP53, may function similarly to induce de-differentiation in
astrocyte-derived human GBM.
The RB family of pocket proteins controls G1/S cell cycle pro-
gression and includes pRB, p107, and p130 encoded by RB,
RBL1, and RBL2. In contrast to RB1, RBL1 (0.4%) and RBL2
(0%) mutations are extremely rare or completely absent in
human GBM.14,47We ablated the G1/S checkpoint in TRP astro-
cytes with T121, a truncated SV40 large Tantigen that function-
ally inactivates all 3 Rb proteins but does not affect
Trp53.17,18,20,21 We and others have found that Rb1 deletion
alone fails to recapitulate the effects of T121 in mouse astro-
cytes (Vitucci, et al, unpublished manuscript), suggesting that
Rbl1 and/or Rbl2 compensate for Rb1 loss in these cells.48 Sim-
ilar compensation has been found in the developingmouse eye,
where Rb1-deficient retinoblasts fail to develop into retinoblas-
toma, a tumor initiated by homozygous RB1 loss in humans.
Rather, mouse retinoblasts express all 3 pocket proteins, and
simultaneous deletion of Rb1 and either Rbl1 or Rbl2 is required
to transform these cells.49 Furthermore, deletion of all 3 Rb
genes is required to ablate the G1/S checkpoint and induce pro-
liferation of mouse embryonic stem cells and fibroblasts.50
Taken together, these findings suggest that humans and
mice may have species-specific differences in RB family gene
expression that alter their susceptibility to RB1-mediated
tumorigenesis in particular cell types.
Transcriptome subtypes of GBMmimic the profiles of purified
mouse brain cells including NSCs, astrocytes, and OPCs.13,14
GEM modeling studies have shown that all 3 represent candi-
date cells of origin for GBM.15,17,18,20,42,48,51,52 NSCs have re-
ceived the most attention due to their phenotypic similarity
to GSCs. Indeed, many mutated GBM genes, including Rb1,
Kras, and Pten, regulate NSC self-renewal, proliferation, and dif-
ferentiation in mice.53–55 These findings suggest that NSCs and
GSCs share biological features. However, cancer cell lineage re-
lationships are plastic.56 The initially mutated cell may differ
from the cell type that actually drives tumor growth. Indeed,
genetic lineage tracing in GEM has shown that OPCs drive
tumor growth when Trp53 and Nf1 are deleted in embryonic
NSCs, suggesting that transformation is triggered only after dif-
ferentiation.57 Conversely, these mutations transform astrocytes
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and induce their de-differentiation into more primitive cells.42
Cancer cell lineage plasticity thus precludes identifying tumor or-
igins simply by comparing tumor transcriptomes to normal brain
cells: it fails to account for mutation-induced plasticity. More ex-
tensive use of genetic lineage tracing in GBMmousemodels driv-
en by different oncogenic mutations in different cells of origin
will aid in defining the cellular and genetic conditions under
which lineage plasticity occurs and the extent to which it affects
genomic tumor profiles.
We have previously shown that TRP mutations induce GBM
in GFAP+ astrocytes of adult mice.20 We recently used genetic
lineage tracing and fatemapping to show that transformed TRP
astrocytes express NSCmarkers within days of tumor induction,
suggesting that de-differentiation occurs in situ.58 Similar
results were obtained in GEMmodels with alternative combina-
tions of G1/S, MAPK-PI3K, and TP53 pathway mutations.
Combining Trp53 loss and activating MAPKmutations, including
oncogenic Hras or Nf1 loss, transformed mouse astrocytes, but
both were required to induce de-differentiation in vitro.42 Trp53
and Pten loss also transformed mouse astrocytes, but their
effects on de-differentiation were not examined.48 Together
these results suggest that ablation of all Rb family members
via T121 or Cdkn2a deletions affecting both p16
Ink4a and p19Arf,
but not Trp53 loss alone, is sufficient to induce astrocyte
de-differentiation. They also suggest that either RTK mutations
(EGFRvIII) or the cooperative effects of MAPK (oncogenic Ras,
Nf1 deletion) and PI3K pathway mutations (Pten deletion) are
required to drive de-differentiated astrocyte tumorigene-
sis.17,20,41,42,48 We conclude that cortical astrocytes, the most
abundant cell type in the mammalian brain, are likely cells of
origin for GBM.
GSCs are thought to be inherently resistant to XRT and che-
motherapy.6,7 We found that de-differentiated TRP astrocyte
GSCs were resistant to TMZ and expressed MGMT, like their nor-
mal NSC and astrocyte counterparts, suggesting that MGMT is
one mechanism of TMZ resistance in this model system. Howev-
er, an MGMT-independent mechanism is also likely, particularly
the Hox/stem cell signatures that may mediate resistance in pe-
diatric and adult GBM.59,60These reports found that transcription-
al activation of the Hoxa locus induced increased proliferation
and decreased apoptosis in cultured GBM cells. These effects
were abrogated by PI3K-targeted inhibitors (PI3Ki) through alter-
ations in histone H3K27me3, and their combination with TMZ
was synergistic. Together with our previous findings that a PI3K-
specific signature was upregulated in TRP astrocytes and en-
riched in human proneural GBM,17 these results suggest that
the process of TRP-induced astrocyte de-differentiation into
GSCs also contributes to their TMZ resistance.
TRP allografts were enriched for proneural GBM signatures
and were sensitive to XRT. Recurrent tumors were molecularly
similar to XRT-treated human GBM, and XRT induced a mesen-
chymal shift in tumor transcriptome and morphology.12 Similar
results have been found in humans as well as a PDGF-driven
mouse model of proneural GBM.12,61 We have therefore
shown that this nGEM model system recapitulates proneural
GBM on the histopathological, molecular, and treatment re-
sponse levels and demonstrated its utility for preclinical experi-
mental therapeutics. Because it employs prospectively defined
oncogenicmutations in a specific cell type, this model may com-
plement other systems used in preclinical drug development
where these factors are ambiguous, including established cell
lines or patient-derived xenografts.16 It may be particularly use-
ful for dissecting the genetics of astrocyte de-differentiation and
elucidating cellular and genetic mechanisms of treatment resis-
tance. Transplantation into syngeneic, immunocompetent hosts
offers a platform for developing immunotherapies or drugs that
target tumor-stroma interactions.
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